Advertisement

Picture Berlin Partner Special Topic Well-trained Professionals 650x100px
Document › Details

Prothena Corporation plc. (2/8/17). "Press Release: Prothena to Participate in the Leerink Partners 6th Annual Global Healthcare Conference". Dublin.

Organisations Organisation Prothena Corporation plc (Nasdaq: PRTA)
  Group Prothena (Group)
  Organisation 2 Leerink Partners LLC
  Today SVB Leerink LLC
Products Product Leerink Partners Annual Global Healthcare Conference 2017 New York
  Product 2 therapeutic antibody
Index term Index term Prothena–Leerink: investor conference, 201702 supply service Prothena presents at Leerink Partners Global Healthcare Conference in NYC
Persons Person Nguyen, Tran (Prothena 201701 CFO)
  Person 2 Rose, Ellen (Prothena 201701 Public Relations)
     


Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Leerink Partners 6th Annual Global Healthcare Conference on February 16th at 11:30 AM ET in New York, NY.

A live webcast of the company presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.


About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena is establishing a fully integrated research, development and commercial focus and has advanced several drug candidates into clinical studies while pursuing discovery of additional novel therapies. Our pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis (PRX004). For more information, please visit the company's website at www.prothena.com.


Contacts

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose, Head of Communications
650-922-2405, ellen.rose@prothena.com

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group Biotech Showcase 2024 San Francisco 650x200px

More documents for Prothena (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x300px




» top